Supine and upright hemodynamic measurements were performed in 10 patients with chronic congestive heart failure, before and during vasodilator therapy with hydralazine and isosorbide dinitrate. This combination of drugs produced significant improvement in supine hemodynamic measurements, with the pulmonary capillary wedge pressure decreasing from 26 ± 5 to 18 ± 5 mm Hg (mean ± SD, p < 0.01) and stroke volume index increasing from 25 ± 6 to 39 ± 6 ml/mi (p < 0.01), without any significant change in heart rate (HR) or mean arterial pressure (MAP). However, with the patients upright, HR rose significantly (87 ± 17 to 99 ± 17 beats/min,p < 0.05) and MAP fell (84 ± 10 to 66 ± 11 mm Hg,p < 0.001) compared with measurements before treatment. These patients also exhibited potentially deleterious postural changes in HR, MAP, cardiac output, stroke volume index and stroke work index during therapy with the combination of hydralazine and isosorbide dinitrate. Although diuretic therapy (which had been withheld for 12 hours in eight subjects but only for 6 hours in two others) may have played a role in producing these changes, postural hypotension or tachycardia was not noted before vasodilator therapy or during therapy with nitrates or hydralazine. Repeat catheterization after 3 months in six patients revealed a lessening of the postural effects. These findings indicate the need to perform upright as well as supine hemodynamic measurements during the initiation of vasodilator therapy and suggest the need for particular caution in patients with ischemic heart disease.
SUMMARY Supine and upright hemodynamic measurements were performed in 10 patients with chronic congestive heart failure, before and during vasodilator therapy with hydralazine and isosorbide dinitrate. This combination of drugs produced significant improvement in supine hemodynamic measurements, with the pulmonary capillary wedge pressure decreasing from 26 ± 5 to 18 ± 5 mm Hg (mean ± SD, p < 0.01) and stroke volume index increasing from 25 ± 6 to 39 ± 6 ml/mi (p < 0.01), without any significant change in heart rate (HR) or mean arterial pressure (MAP). However, with the patients upright, HR rose significantly (87 ± 17 to 99 ± 17 beats/min,p < 0.05) and MAP fell (84 ± 10 to 66 ± 11 mm Hg,p < 0.001) compared with measurements before treatment. These patients also exhibited potentially deleterious postural changes in HR, MAP, cardiac output, stroke volume index and stroke work index during therapy with the combination of hydralazine and isosorbide dinitrate. Although diuretic therapy (which had been withheld for 12 hours in eight subjects but only for 6 hours in two others) may have played a role in producing these changes, postural hypotension or tachycardia was not noted before vasodilator therapy or during therapy with nitrates or hydralazine. Repeat catheterization after 3 months in six patients revealed a lessening of the postural effects. These findings indicate the need to perform upright as well as supine hemodynamic measurements during the initiation of vasodilator therapy and suggest the need for particular caution in patients with ischemic heart disease.
THE USE of drugs that dilate the peripheral vasculature to treat chronic heart failure is increasing in popularity.' 2 The nitrates, hydralazine and prazosin, the most frequently used of these medications, often produce an increase in heart rate or a decrease in blood pressure in normal subjects and in hypertensive patients without left ventricular failure. In contrast, numerous studies of these agents in patients with congestive heart failure have shown an increase in cardiac output and a reduction of left ventricular filling, with no change in heart rate and with only slight, if any, reduction of arterial pressure. [3] [4] [5] [6] [7] [8] [9] [10] [11] Most of these studies have dealt only with supine patients. We have noted potentially deleterious hemodynamic responses after the assumption of upright posture in patients given a combination of hydralazine and isosorbide dinitrate in doses chosen to produce optimal improvement in supine measurements. In this report, we describe the hemodynamic effect of postural change in a group of patients before and during treatment with these medications.
Methods
We studied 10 consecutive patients with New York Heart Association class 3 or 4 chronic congestive heart failure, referred for vasodilator therapy because of symptoms refractory to treatment with digitalis and diuretics. Seven patients had ischemic heart disease, two had primary cardiomyopathy and one patient had hypertensive heart disease.
In each patient, a balloon flotation thermodilution catheter was placed in the pulmonary artery and a plastic cannula was inserted in a radial artery. For measurement of both supine and upright pressures, the transducers were placed at a height 5 cm below the angle of Louis. After reproducible baseline measurements of heart rate, arterial, right atrial, pulmonary artery and pulmonary capillary wedge pressures and cardiac output were obtained in the supine position, the patients sat up as a prelude to performing bicycle exercise. Measurements were then recorded over a 5minute period beginning 3 minutes after assumption of the upright position.
The patients began taking 5 mg of sublingual isosorbide dinitrate every 2-3 hours while awake, and the dose was increased until the supine pulmonary capillary wedge pressure decreased to 15 mm or to a maximal dose of 15 mg. Supine and upright measurements were repeated 20-40 minutes after the preceding isosorbide dinitrate dose, and the drug was then discontinued temporarily. Next, the patient began to take 50 mg of oral hydralazine every 6 hours, and the dose was increased until supine cardiac index exceeded 2.5 1/min/M2 or to a maximal dose of 100 mg every 6 hours. After repeat measurements 2-3 hours after the last dose of hydralazine, isosorbide dinitrate was restarted. The final measurements were obtained in the same way on combined therapy.
During the 72 hours of monitoring, patients were allowed to walk near their beds and to sit in a chair several times daily. All medications except for hydralazine and isosorbide dinitrate were continued at previous dosages. Diuretics were withheld for 12 hours before each set of measurements in eight patients and for 6 hours in the remaining two (nos. 1 and 6). No patient had more than a 1-lb weight change during the study. No patient was on other medications known to produce hypotension, and none had previous evidence of pathologic postural fluctuations of heart rate or blood pressure.
Six patients returned after 3 months for elective recatheterization while continuing their medications at the previous dosages. Supine and sitting measurements were then obtained at the same time after the administration of hydralazine and isosorbide dinitrate.
Derived hemodynamic variables were calculated as follows: SVI = CO/BSA SWI = 0.0136 X SVI X (SAP -PCW) SAP = DAP X 0.67 X (SAP -DAP) where SVI is stroke volume index, CO is cardiac output, BSA is body surface area, SWI is stroke work index, SAP is mean systolic arterial pressure, PCW is pulmonary capillary wedge pressure and DAP is diastolic arterial pressure.
Two-way analysis of variance with a mixed-effects model was used to determine the significance of differences between supine and sitting measurements before and during vasodilator therapy and, for the recatheterized subjects, at the initiation of vasodilators and after 3 months on medications. All values are expressed as mean ± SD.
Results

Effect of Combined Vasodilator Therapy on Supine and Upright Hemodynamic Measurements
The supine and upright values for several hemodynamic variables before and during vasodilator therapy are given in table 1 EUSITTING 39 ± 6 ml/m2) and stroke work index (24 ± 9 to 38 ± 8 g-m/m2) and a substantial decrease in pulmonary capillary wedge pressure (26 ± 5 to 18 ± 4 mm Hg), without significant change in heart rate or arterial pressure. With the patients sitting, the improvement in stroke volume index was less dramatic (23 ± 6 to 30 ± 6 mI/M2) and the rise in stroke work index was no longer significant (25 ± 10 to 28 ± 8 g-m/m2). The decrease in pulmonary capillary wedge pressure with hydralazine and isosorbide dinitrate was greater with the patients upright (24 ± 6 to 13 ± 5 mm Hg), and right atrial pressure fell to very low levels in many patients. The heart rate increased and the arterial pressure decreased significantly during combined hydralazine and isosorbide dinitrate therapy when the patients were upright. Before vasodilators, there were no significant hemodynamic differences with change in position. During therapy with hydralazine and isosorbide dinitrate, a significant increase in heart rate and significant decreases in arterial pressures, right atrial pressure, pulmonary capillary wedge pressure, stroke volume index and stroke work index all occurred as the patients rose from a supine to a sitting position ( fig. 2 ). Although the mean changes with the shift in posture were small, six patients had marked decreases in stroke volume accompanied by a decrease in blood pressure and an increase in heart rate ( fig. 3 ). Thus, heart rate increased by at least 15 beats/min in five subjects and mean arterial pressure declined by 15 mm Hg in three patients and by as much as 25 mm Hg in one. Two patients experienced dizziness, and one of them, near-syncope. Four of the six patients with the most marked positional changes had decreases in their left ventricular filling pressure to 13 mm Hg or below while upright, but two others had sitting pulmonary capillary wedge pressures of 21 mm Hg and 16 mm Hg and nonetheless exhibited postural tachycardia and hypotension. These postural hemodynamic effects persisted for up to 10 minutes in the sitting position, but rapidly disappeared when the patients began to exercise. Table 1 shows the hemodynamic measurements obtained with isosorbide dinitrate and hydralazine alone. With patients both supine and sitting, isosorbide dinitrate reduced left ventricular filling pressure with little effect on stroke volume, whereas hydralazine markedly increased stroke volume and had a lesser effect on pulmonary capillary wedge pressure. Neither medication significantly changed heart rate or blood pressure in either position. Marked hemodynamic changes with shifts in posture did not occur with individual therapy, in contrast to the findings with combined therapy (fig. 2 ).
Effect of Long-Term Vasodilator Therapy on Postural Changes
The postural changes appeared to lessen with time in the six patients restudied after 3 months (table 2) . At 3 months, the increase in heart rate after assuming upright posture was 7 ± 5 beats/min, compared with the earlier increase of 14 ± 8 beats/min, and the reductions in blood pressure and stroke volume index were6 8mmHgvs 10 ± 9mmHgand6 + 6mI/m2 vs 12 7 ml/m2. Nonetheless, these changes remained marked in two patients, although they were no longer associated with symptoms.
Discussion
There is a great deal of evidence that vasodilators produce hemodynamic improvement in patients with chronic congestive heart failure.'-" Although all of the medications commonly used for this purpose may produce tachycardia and a decrease in blood pressure in normal subjects, no significant changes in heart rate and, at most, only small reductions in arterial pressure have been noted with vasodilator therapy in patients with severe left ventricular dysfunction. However, these reports have generally dealt with supine measurements.
In our subjects, obvious postural effects were present while the patients were taking vasodilators and were not present without these medications. Although the mean differences between supine and upright heart rate and blood pressure were small, they were significant for the group as a whole and striking in some individuals. These postural changes were large enough to produce symptoms in some patients and, potentially, to provoke ischemia in susceptible patients.
These changes could not be predicted from the supine measurements. Indeed, the medication doses had been chosen to optimize the supine measurements. For the group, there were no significant changes in supine heart rate or blood pressure with the administration of vasodilators, and individual changes were not impressive. The most likely mechanism of these postural changes is reduced venous return secondary to peripheral pooling. The finding that most patients who demonstrated marked postural changes in heart rate, arterial pressure or stroke volume also had relatively low upright left and right ventricular filling pressures supports this inference. The rapid disappearance of the postural vasodilator effects with the onset of exercise is also consistent with this explanation. While nitrates, as predominant venodilators, might be expected to play the major role in producing these postural changes, this phenomenon was not observed after administration of isosorbide dinitrate alone. Our findings suggest that a combination of an arteriolar dilator and a venodilator is required, although the mechanism by which these agents act synergistically is unclear.
The lessening of postural changes with chronic therapy may reflect a compensatory increase in intravascular volume, possibly mediated by increased activity of the renin-angiotensin system,12 or it may reflect some attenuation of the vasodilating action of the drugs. This latter phenomenon has been noted with prazosin but has not been described with hydralazine or isosorbide dinitrate. [13] [14] [15] [16] Only one preliminary report has addressed the question of postural changes in heart failure patients receiving vasodilators. Franciosa et al.l' noted no difference between sitting measurements in patients given a single dose of hydralazine and isosorbide dinitrate in combination and those given placebo. Although they did not specifically compare supine and sitting measurements in their abstract, they concluded that vasodilator drugs do not have harmful postural effects.
Several differences in the study protocols may explain the differing findings. Their patients were studied after a single dose of medication, and oral, rather than sublingual, isosorbide dinitrate was used. Hydralazine appears to produce greater hemodynamic changes with repeated dosing,6 and sublingual nitrates may have a more intense peak effect. In addition, our patients may have been somewhat deconditioned by 3 days of restricted activity. However, some degree of postural changes persisted even after 3 months of continuous therapy when the patients were studied without preceding activity limitation. Franciosa and Cohn '7, 18 have reported the occasional occurrence of orthostatic symptoms in heart failure patients given isosorbide dinitrate and a small, but significant, decrease in sitting blood pressure after the combination therapy with hydralazine and isosorbide dinitrate.
Our patients continued to receive diuretic therapy. Although these medications had been withheld for at least 6 hours and usually for 12 hours, they may still have played a role in producing the observed hemodynamic findings. However, because almost all patients receiving chronic vasodilator therapy are maintained on diuretics, our findings remain clinically relevant. Further, postural hypotension and tachycardia were not present during control measurements in patients on individual therapy made at a similar time after diuretic administration and with the patients at the same body weight. Thus, it is likely that these changes resulted predominantly from the vasodilators themselves.
Implications
The occurrence of these postural hemodynamib changes in patients receiving isosorbide dinitrate and hydralazine in combination has important clinical implications. While the magnitude of these postural changes was generally small and should be well tolerated in most patients receiving these agents, the resulting tachycardia and decrease in blood pressure, previously unrecognized in this setting, may occasionally be hazardous. Measurements of supine and upright heart rate and blood pressure, as well as other hemodynamic variables in catheterized patients, should become routine, so that patients with marked postural changes can be detected. Medication dosing should not be based upon supine measurements alone.
Special care must be taken in administering vasodilators to outpatients without the use of hemodynamic monitoring. Prazosin and other agents used for vasodilator therapy should be evaluated to see if these also produce postural changes. Until postural changes are found not to be present in individual subjects, it may be prudent to treat those with ischemic heart disease with lower initial dosages of vasodilators.
MOST STUDIES of the prognostic significance of premature ventricular complexes (PVCs) have emphasized the importance of the "complex" features and frequency of the PVCs in determining prognosis.'~" Complex features include multifocality, presence of two (couplets) or more (runs) consecutive PVCs and the R-on-T phenomenon. Elimination of the specific "4malignant forms" with or without reduction of overall PVC rates may be a reasonable goal of therapy designed to protect against symptomatic ventricular tachycardia or sudden death.`However, previous evaluations of the effectiveness of antiarrhythmic agents have usually focused simply on the total number of PVCs. An accurate measurement of the effects of antiarrhythmic agents on specific forms of ventricular ectopic beats could not be performed because of limitations of standard Holter analysis techniques.
The Argus/H computerized Holter analysis system allows enumeration of PVCs, couplets and runs subgrouped by coupling intervals.7 In this study, we used this analytic capability to evaluate the therapeutic activity of phenytoin, quinidine and procainamide against these complex PVCs.
Methods
Thirteen patients (11 men and two women) who had multifocal PVCs, couplets or runs and who had an average PVC rate of over 50/hour on each of two qualifying 10-hour ambulatory Holter recordings were enrolled in this study. All patients had coronary heart disease, and all had survived one or more myocardial infarctions 3-35 months before the study. Two patients had undergone coronary bypass surgery 6 and 11 months previously. The patients ranged in age from 50-70 years. No patient had hepatic or renal disease, uncompensated heart failure or atrioventricular block. Seven patients continued taking digoxin; serum levels were measured and dosage was initially adjusted to maintain a level of 1-2 ng/ml. Serum potassium was measured weekly and maintained at greater than 3.5 mEq/l. Patient 1 had been taking 20 mg of propranolol four times a day for control of angina before the study, and continued this regimen through- 664 CIRCULATION
